Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells

At present, 20–30% of children with acute leukemia still relapse from current chemotherapy protocols, underscoring the unmet need for new treatment options, such as proteasome inhibition. Ixazomib (IXA) is an orally available proteasome inhibitor, with an improved safety profile compared to Bortezom...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cells
Main Authors: Roeten, Margot S.F., van Meerloo, Johan, Kwidama, Zinia J., ter Huizen, Giovanna, Segerink, Wouter H., Zweegman, Sonja, Kaspers, Gertjan J.L., Jansen, Gerrit, Cloos, Jacqueline
格式: Artigo
語言:Inglês
出版: MDPI 2021
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC8002577/
https://ncbi.nlm.nih.gov/pubmed/33802801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells10030665
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍